Earnings call transcript: HLS Therapeutics Q3 2026 misses estimates as stock falls 9%

HLS Therapeutics reported Q3 2026 earnings that fell short of Wall Street expectations, with the company's stock falling 9% in premarket trading. The specialty pharmaceutical company posted revenue of $14.16 million, a 5% increase from the previous year, which was still below forecasts for $14.88 million. Adjusted loss per share was $0.07, surpassing expectations by 14%.

The cardiovascular portfolio saw a 21% growth in local currency, while NILEMDO and VASCEPA continued to gain traction. However, Clozaril sales declined in both Canada and the United States, raising concerns about the impact on overall profitability. Despite the earnings miss, HLS executives noted early signs of scaling in their cardiovascular strategy and pointed to improving operating leverage.

The company expects 2027 to bring stronger revenue and Adjusted EBITDA growth, driven by factors such as public reimbursement for NILEMDO, potential Health Canada decisions, and the launch of NEXLIZET and VERQUVO.